SCHEMBL454827

SCHEMBL454827

O=C1c2ccccc2C(=O)N1N1C(=O)c2ccccc2C1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.67
KMT2A Q03164 5/20 0.56
ELANE P08246 1/20 0.52
MEN1 O00255 3/20 0.50
CDC25B P30305 2/20 0.50
GAA P10253 1/20 0.50
CASP3 P42574 1/20 0.50
EHMT2 Q96KQ7 2/20 0.48
EHMT1 Q9H9B1 2/20 0.48
CYP1A2 P05177 1/20 0.48
MAOA P21397 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CES2 O00748 1/20 0.47
APAF1 O14727 1/20 0.47
TERT O14746 1/20 0.47
NPC1 O15118 1/20 0.47
PLIN1 O60240 1/20 0.47
TDP2 O95551 1/20 0.47
S1PR4 O95977 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022462 0.97 POLB (0.64) POLBKMT2AELANEMEN1CDC25B
SCHEMBL28160078 0.97 POLB (0.64) POLBKMT2AELANEMEN1CDC25B
SCHEMBL11229948 0.87 POLB (0.54) POLBKMT2AELANEMEN1CDC25B
SCHEMBL3992123 0.84 POLB (0.52) POLBKMT2AELANEGAACASP3
SCHEMBL12464402 0.84 POLB (0.52) POLBKMT2AELANEMEN1CDC25B
SCHEMBL13896437 0.81 POLB (0.54) POLBKMT2AELANEMEN1CDC25B
SCHEMBL30022123 0.81 POLB (0.54) POLBKMT2AELANEMEN1CDC25B
SCHEMBL1965970 0.81 POLB (1.00) POLBKMT2AELANEMEN1CDC25B
SCHEMBL3204064 0.81 POLB (0.48) POLBKMT2AELANEMEN1GAA
SCHEMBL29010701 0.81 CES1 (0.55) POLBGAACASP3MAOACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017081676-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER PHARMATWOB (IL) 2017-05-18 WO claimed
US-20130149243-A1 METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-13 US claimed
US-5049601-A For polymers ETHYL CORPORATION (US) 1991-09-17 US claimed
US-11491245-B2 Gadolinium chelate compounds for use in magnetic resonance imaging BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-11-08 US disclosed
CN-109219606-B Halogen substituted piperidines as orexin receptor modulators 阿斯利康(瑞典)有限公司 2021-10-01 CN disclosed
US-20200353104-A1 GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-11-12 US disclosed
CN-109219606-A The piperidines that the halogen of orexin receptor regulator replaces 阿斯利康(瑞典)有限公司 2019-01-15 CN disclosed
CN-108362791-A Phthalimide detection method in a kind of tealeaves 中国农业科学院茶叶研究所 2018-08-03 CN disclosed
CN-108117645-A The poly- fragrant acid imide manufacturing method of one kind and its process units 梅雪 2018-06-05 CN disclosed
WO-2017081676-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER PHARMATWOB (IL) 2017-05-18 WO disclosed
US-9592308-B2 Method for production of F-18 labeled amyloid beta ligands PIRAMAL IMAGING SA (CH) 2017-03-14 US disclosed
US-20090107551-A1 Organic electronic devices using phthalimide compounds ENERGY, U.S. DEPARTMENT OF 2009-04-30 US disclosed
US-20090107551-A1 Organic electronic devices using phthalimide compounds ENERGY, U.S. DEPARTMENT OF 2009-04-30 US disclosed
WO-2007120788-A1 ORGANIC ELECTRONIC DEVICES USING PHTHALIMIDE COMPOUNDS THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2007-10-25 WO disclosed
EP-1812028-A2 HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY YALE UNIVERSITY (US) 2007-08-01 EP disclosed
WO-2006053049-A2 HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY YALE UNIVERSITY (US) 2006-05-18 WO disclosed
US-20050196473-A1 Herbal composition PHY906 and its use in chemotherapy KADMON CORPORATION, LLC 2005-09-08 US disclosed
US-4444264-A PHTHALIMIDE PARTICLES HALLIBURTON COMPANY (US) 1984-04-24 US disclosed
US-4310461-A HYPTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1982-01-12 US disclosed
US-3933507-A LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER AGFA-GEVAERT, A.G. (DT) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11491245-B2 Gadolinium chelate compounds for use in magnetic resonance imaging GLRA1, GLRA3, GLRB POLB 3836/4885KMT2A 3983/4885ELANE 4048/4885
US-20130149243-A1 METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES GLUL, SLC18A2, SLC1A2 POLB 3501/4885KMT2A 708/4885ELANE 4502/4885
US-20200353104-A1 GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING GLRA1, GLRA3, GLRB POLB 3836/4885KMT2A 3983/4885ELANE 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.